AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06251167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge plus custom arch support (LWAS)
Description: Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. These insoles will be designed based on an innovative tablet-based app designed by industry partner Kintec Footlabs, who will be the provider of the insoles for this project. Using the high-fidelity 3D scanning tool available (Apple's True Depth sensor), the Epitek Self-Scanner app captures tens of thousands of 3D data points within a single 1-second capture, and then uploads this foot data to a secure patient record system that is used for insole fabrication. The LWAS insoles will be comprised of variable density material (more dense laterally than medially) and milled directly to produce a full-length shell. The 6 degree wedge will be incorporated along the full lateral length of the insoles.
Study NCT05544526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2 CAR T cells
Description: Infusion with: GD2 CAR T-cells
Study NCT06525298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIS-12656
Description: EIS-12656 tablets given daily
Study NCT06525298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: as per USPI/SmPC
Study NCT06525298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: as per USPI/SmPC
Study NCT05541926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Connect
Description: Implementation of the e-Connect system
Study NCT04723511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants on the treatment sequence. This will be a session of Kendall's exercises as described below. This will followed be by performing GPR techniques of Anterior Chain stretch in the supine frog-like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Starting from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session fourth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take about 90 minutes.~Pre-treatment diaphragmatic release and deep breathing exercises are applied at the beginning of each session
Study NCT04723511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kendall exercises
Description: exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop.
Study NCT04723511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kendall exercises
Description: exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop.
Study NCT06126614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 0.05% chlorhexidine gluconate solution for irrigation
Study NCT06126614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Hydrochloride
Description: 2 grams of topical vancomycin hydrochloride added to the wound
Study NCT06126614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: 0.35% povidone-iodine solution for irrigation
Study NCT06126614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline for irrigation
Study NCT06126614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: saline for irrigation
Study NCT04805502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
Study NCT04687306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: X-rays- total of 4
Description: X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
Study NCT06251557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic Massage
Description: 10 minutes abdominal massage and 10 minutes lower back massage will be applied in each session. It will take 20 minutes in total.
Study NCT06251557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training will last approximately 10 minutes in each session. In the exercise training, lumbopelvic stabilization exercises (bridge, cat-and-cow and squatting exercises) will be performed for 10 repetitions, lumbopelvic flexibility exercises (child position, happy baby position, adductor muscle stretching, psoas muscle stretching) will be performed for 20 seconds and 5 repetitions, and diaphragmatic breathing exercises will be performed for 5 repetitions in supine, side lying and sitting positions.
Study NCT06251557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Electromyography (EMG) Biofeedback Therapy
Description: Biofeedback therapy will be applied for 20 minutes in each session. During the application, adhesive surface electrodes will be placed on the perineum at 4 o'clock and 8 o'clock for each child. Through these electrodes, the activity signals of the muscles in that area will be recorded superficially. By monitoring the regional muscle activity, feedback is provided to increase and/or decrease the activity according to the activity pattern. As a result, pelvic floor biofeedback therapy will teach the child the correct use of the pelvic floor muscles. During the session, pelvic floor awareness and relaxation exercises specific to the child will be practiced with visual animations.
Study NCT06251557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Electromyography (EMG) Biofeedback Therapy
Description: Biofeedback therapy will be applied for 20 minutes in each session. During the application, adhesive surface electrodes will be placed on the perineum at 4 o'clock and 8 o'clock for each child. Through these electrodes, the activity signals of the muscles in that area will be recorded superficially. By monitoring the regional muscle activity, feedback is provided to increase and/or decrease the activity according to the activity pattern. As a result, pelvic floor biofeedback therapy will teach the child the correct use of the pelvic floor muscles. During the session, pelvic floor awareness and relaxation exercises specific to the child will be practiced with visual animations.
Study NCT06251557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Urotherapy
Description: The anatomy of the urinary system and related structures, the causes of voiding dysfunction and symptoms will be explained to the family and the child with visuals. A written form including timed voiding during the day, appropriate fluid intake, correct toilet posture, adequate and balanced nutrition will be given.
Study NCT06251557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Urotherapy
Description: The anatomy of the urinary system and related structures, the causes of voiding dysfunction and symptoms will be explained to the family and the child with visuals. A written form including timed voiding during the day, appropriate fluid intake, correct toilet posture, adequate and balanced nutrition will be given.
Study NCT05009498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 supplementation
Description: Vitamin D3 in 50,000 IU capsules Loading dose of 150,000 IUs (3 capsules) Interval dosing of 50,000 IUs (1 capsule) every 2 weeks for 1 year
Study NCT05009498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, identical in appearance to the Vitamin D3 supplement capsule Dosing intervals identical in duration and quantity as Vitamin D3 supplement group
Study NCT05535894 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation of Celiac Ganglion
Description: Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
Study NCT05690841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration (fMDA)
Description: Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by 9-11 month intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for >= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals >=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for >= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals >=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing).
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Dose 20 mg once a day (QD)
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Dose 500 mg QD
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Dose: 240 mg QD (combination with trastuzumab)
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Dose: 450 mg QD (Combination with binimetinib)
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Dose: 45 mg twice a day (BID) (Combination with encorafenib)
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Dose: 200 mg QD or 300 mg QD
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
Study NCT05615818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
Study NCT06136169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder-cue scanning training
Description: Auditory reminders to scan when scanning to the side of the field loss is inadequate
Study NCT06338774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Computerized cognitive training completed on any computer or tablet with internet
Study NCT06338774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Computerized cognitive training completed on any computer or tablet with internet
Study NCT06338774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
Study NCT06338774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
Study NCT05161377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical management
Description: Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
Study NCT05161377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular management
Description: Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
Study NCT05025787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6970
Description: CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
Study NCT05025787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID
Study NCT06518954 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: The athletes contributes with experience exchange through individual interviews, following a interview template
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Day 1 Cycle 1-6: Dexrazoxane 500 mg/m2 (iv) will be given 30 minutes before doxorubicin infusion and should be infused during 15 minutes.
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 1 Cycle 1-6: 375 mg/m2 (iv)
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day 1 Cycle 1-6: 750 mg/m2 (iv)
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1 Cycle 1-6: 50 mg/m2 (iv)
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv)
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Day 1-5 Cycle 1-6: 100 mg (oral)
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.
Study NCT06220032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.
Study NCT05305443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation Services
Description: Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
Study NCT05305443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Counseling
Description: Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
Study NCT05305443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
Study NCT05305443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral and Digital Brochure
Description: Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
Study NCT06202365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body Vibration
Description: A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
Study NCT06202365 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Whole body vibration
Description: They will receive the same intervention while the device turned off for 4 minutes, 2 times /week for 6 weeks.
Study NCT05273567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guanfacine-ER
Description: guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.
Study NCT05273567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be dispensed similar to the active arm.
Study NCT05017415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uroflow measurement
Description: Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
Study NCT05017415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder ultrasound
Description: Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
Study NCT06602518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic Treatment
Description: All the enrolled patients will undergo conventional fixed appliance therapy by bonding straight wire Roth appliance in the maxillary arch. The bonding procedure will be standardized in all patients and performed by the same operator using light-cured composite. Levelling and alignment will then be started using the following wire sequence: 0.014-in nickel titanium (NiTi), 0.018-in NiTi, 17×25-in Niti, and 19×25-in Niti arch wires. The upper arch will then be stabilized using a 19×25-in stainless steel (SS) arch wire for 2 months. This stage will require approximately 6 months of treatment.
Study NCT06706037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 6 week reformer pilates exercise program
Study NCT06705556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique, incentive spirometer, percussion, 3-minute of walking
Description: The intervention group:~patients were asked to perform Active cycle of breathing technique as add on to routine chest physical therapy such as Incentive spirometer, percussion, 3-minute of walking 3 days before surgery and five days postoperative.~* Incentive spirometry, 3 sessions per day, 10 repetitions~* Percussions, 3 sessions per day, 20 repetitions~* 3-minutes walking, 2 sessions per day~* ACBT, 3 sessions per day the following were included postoperatively:~* Nebulization, 3 sessions per day~* ACBT, 3 sessions per day
Study NCT06705556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incentive spirometer, percussion, 3-minute of walking
Description: The control group The routine CPT was performed 3 days before surgery at the preoperative bay and 5 days after surgery in the ICU with 3 sessions each day.~Preoperative chest physical therapy sessions were followed as:~* Incentive spirometry, 3 sessions per day, 10 repetitions.~* Percussions, 3 sessions per day, 20 repetitions.~* 3-minutes walking, 2 sessions per day The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3-minutes walking, 2 sessions per day
Study NCT06704425 — intervention group
Intervention type: OTHER
Intervention: For observational studies, participants are not assigned an intervention as part of the study.
Description: For observational studies, participants are not assigned an intervention as part of the study.
Study NCT06705231 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Aarhus-intervention
Description: A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
Study NCT06551051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.